Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (969)	8/13/1998 10:17:00 AM
From: Jack Ucci	Read Replies (1) \| Respond to of 1605

News: Vasomedical Inc. Announces Five Abstracts Accepted for Congress of the European Society of Cardiology Business Wire - August 11, 1998 07:46 WESTBURY, N.Y.--(BW HealthWire)--Aug. 11, 1998--Vasomedical Inc. (Nasdaq:VASO) Tuesday announced that the European Society of Cardiology has accepted five abstracts about the company's Enhanced External Counterpulsation EECP(R) technology for the society's 20th Congress. The papers, including three from Europe and two from the United States, will be presented Aug. 23 and 26 in Vienna, Austria. "A large scientific bibliography is central to the wide acceptance of new medical technologies," said Anthony Peacock, Vasomedical's vice president of Clinical Affairs. "It is gratifying to note that the EECP(R) procedure is increasingly recognized as a significant therapeutic modality in scientific circles." The three papers from Europe (based on trials carried out in three German universities) add new information about the physiological effects of the EECP(R) procedure. One of the two abstracts from the United States discusses quality-of-life benefits reported for patients who have completed a full course of EECP(R) therapy. The other presents the benefits of EECP(R) therapy in patients with angina refractory to revascularization procedures, as observed in a prospective, randomized, controlled multicenter study. The Congress of the European Society of Cardiology is attended by thousands of cardiologists from many countries and is frequently the venue for the worldwide release of breakthrough clinical trial results.